KRAS G12D

About Oncogenuity

Oncogenuity is a preclinical-stage biotech leveraging a proprietary oligonucleotide platform to develop gene-silencing therapies that act at the DNA level. Its lead asset targets the historically 'undruggable' KRAS G12D mutation prevalent in pancreatic, colorectal, and other cancers, with a significant estimated market opportunity. The company, founded in 2018 and based in Cambridge, USA, is also exploring the platform's utility against COVID-19 and various genetic disorders, positioning it in the high-potential but high-risk RNA and gene therapy sector.

Therapeutic Areas